Alnylam Buys More RNAi Patents From Nucleonics

Xconomy Boston — 

Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) said today it has acquired a load of intellectual property that includes more than 100 active patent applications and 16 issued patents worldwide from Langhorne, PA-based Nucleonics. The intellectual property is meant to strengthen Alnylam’s grip on its right to develop drugs using RNA Interference technology, or gene silencing. Terms of the purchase weren’t disclosed, although Alnylam said it still expects to finish the year with more than $500 million in cash and investments, as it previously forecast.

By posting a comment, you agree to our terms and conditions.

Comments are closed.